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Summary
We examined whether tolvaptan combined with an angiotensin II receptor blocker (ARB) or angiotensin converting 
enzyme inhibitor (ACE-I) is more effective than tolvaptan alone in the treatment of patients with heart failure (HF). Six-
ty-five hospitalized patients with acute decompensated HF were included in this study. They were divided into 2 groups; 
an ARB/ACE-I group (n = 44, who received ARB or ACE-I before the use of tolvaptan) and a non-ARB/ACE-I group (n 
= 21). There were no significant differences in patient characteristics including medications at baseline between the non-
ARB/ACE-I and ARB/ACE-I groups with the exception of the percentages of hypertension and ischemic heart disease. 
Urinary volume (UV) at baseline in the ARB/ACE-I group was slightly higher than that in the non-ARB/ACE-I group. 
The increase in UV after the use of tolvaptan in the non-ARB/ACE-I group was significantly higher than that in the 
ARB/ACE-I group. The cardiothoracic ratio and the reduction in body weight were similar between the groups after 
tolvaptan use. Finally, in a logistic regression analysis, a response to the use of tolvaptan was independently associated 
with the non-use of ARB/ACE-I, but not with age, gender, body mass index, loop diuretic, or human arterial natriuretic 
peptide. In conclusion, tolvaptan alone might induce an increase in UV in decompensated HF patients without ARB/
ACE-I, although the treatment of HF with ARB/ACE-I is the first choice strategy.   (Int Heart J 2017; 58: 385-392)
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H eart failure (HF) is identified by a typical finding of low cardiac output associated with signs of pulmo-nary and systemic congestion.1-3) In Japan, HF is a 
major health problem, and its prevalence is increasing due to 
the aging population. It is important that patients are provided 
the optimal medications according to the guidelines for HF.4,5)
Loop diuretics are broadly used in the treatment of HF. 
However, high-dose loop diuretics can cause adverse effects 
such as prerenal failure and electrolyte imbalance.6) Tolvaptan 
is a vasopressin type 2 receptor antagonist that is effective in 
patients with HF.7-14) Tolvaptan became available in Japan for 
the treatment of HF in 2010. When sufficient diuresis is not 
achieved with diuretics such as loop diuretics, tolvaptan is rec-
ommended. Recently, a growing body of evidence has sup-
ported the efficacy and safety of tolvaptan in patients who are 
refractory to considerable amounts of loop diuretics.7)
Editorial p.307
Angiotensin converting enzyme inhibitors (ACE-I) and 
angiotensin II type 1 receptor blockers (ARB) are part of a ba-
sic strategy for the treatment of HF.15) ACE-I are recommended 
in patients with HF with reduced ejection fraction and current 
or prior symptoms, unless contraindicated, to reduce morbidity 
and mortality.4) ARBs are recommended in patients with re-
duced ejection fraction with current or prior symptoms who do 
not tolerate ACE-I. ARB/ACE-I are vasodilators that help to 
reduce the workload of the heart, and can block some neurohu-
moral factors that can have adverse effects on HF. ARB/ACE-I 
reduce intraglomerular pressure, which has a renoprotective 
effect, by inhibiting angiotensin II-mediated efferent arteriolar 
vasoconstriction.16)
There have been no reports on the additive or synergistic 
effects of tolvaptan and ARB/ACE-I in patients with HF. Peri-
co, et al reported that a dual type 1a and 2 vasopressin receptor 
antagonist induced a partial antiproteinuric effect, which was 
enhanced by the addition of enalapril or losartan in a model of 
chronic proteinuric nephropathy in rats.17) In addition, activa-
tion of the type 2 vasopressin receptor stimulates renin synthe-
sis via the protein kinase A/cAMP response element-binding 
protein pathway in the collecting duct.18) Therefore, we hy-
pothesized that tolvaptan combined with ARB/ACE-I would 
be more effective than tolvaptan alone in the treatment of pa-
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tients with HF. The purpose of this study was to assess the ef-
fectiveness of tolvaptan with or without ARB/ACE-I therapy 
in HF patients in the acute phase.
Methods
Study population and protocol:   Sixty-five consecutive hospi-
talized patients with acute decompensated HF who initially re-
ceived tolvaptan were retrospectively enrolled. All data were 
collected before the initiation of tolvaptan (at baseline) and for 
the following 10 days. They were divided into 2 groups; an 
ARB/ACE-I group [n = 44, who received ARB (n = 26) or 
ACE-I (n = 18) for 10 days before the use of tolvaptan] and a 
non-ARB/ACE-I group (n = 21, who did not receive ARB or 
ACE-I for 10 days). The study was approved by the ethics 
committee of Fukuoka University Hospital (#15-11-09). We 
collected and analyzed all data using the database of Fukuoka 
University Hospital.
Data collection:   Urinary volume (UV) was obtained for 3 
days before and 10 days after the administration of tolvaptan. 
UV values at baseline (day 0) were calculated as the average 
UV over 3 days before the administration of tolvaptan. Blood 
pressure (BP) was determined using a sphygmomanometer af-
ter at least 5 minutes of rest. Systolic and diastolic BP (SBP 
and DBP) and heart rate (HR) measurements were obtained 
every day. Fasting blood samples were collected at baseline 
and after 10 days (at post). Brain natriuretic peptide (BNP), N-
terminal pro-BNP (NT-proBNP), uric acid (UA), low-density 
lipoprotein cholesterol (LDL-C), high-density lipoprotein cho-
lesterol (HDL-C), triglycerides (TG), total cholesterol (TC), 
and hemoglobin A1c (HbA1c) in blood were measured at 
baseline. Patients with BNP ≥ 100 pg/mL were considered to 
have HF.5) All patients in this study satisfied the criteria. Com-
plete blood count, urea nitrogen (UN), creatinine (Cr), estimat-
ed glomerular filtration rate (eGFR), sodium (Na), potassium 
(K), chloride (Cl), aspartate transaminase (AST), alanine ami-
notransferase (ALT), and lactate dehydrogenase (LDH) in 
blood and urine osmolality were assessed at baseline and after 
10 days.
The patient characteristics with regard to history of hy-
pertension (HTN), dyslipidemia (DL), diabetes mellitus (DM), 
and smoking (current smoker) as cardiovascular risk factors, 
cardiothoracic ratio (CTR), and medication use were obtained 
from medical records. Patients who had a current SBP and 
DBP ≥ 140 and 90 mmHg, respectively, or who were receiving 
antihypertensive therapy were considered to have HTN. Pa-
tients with LDL-C ≥ 140 mg/dL, TG ≥ 150 mg/dL, and/or 
HDL-C < 40 mg/dL, or who were receiving lipid-lowering 
therapy were considered to have DL. DM was defined using 
the Japan Diabetes Society criteria. Body mass index (BMI) 
was calculated as weight (kg)/height (m)2. Chronic kidney dis-
ease (CKD) was defined as an eGFR level of < 60 mL/
minute/1.73m2 or the presence of proteinuria. Hyperuricemia 
(HU) was defined as a serum uric acid (UA) level of ≥ 7.0 mg/
dL or the use of uric acid-lowering drugs. HF was assumed 
based on the medical history including medications and cardi-
ac function. The etiology of HF was classified as ischemic 
heart disease (IHD), hypertensive cardiomyopathy (HTCM), 
valvular heart disease, dilated cardiomyopathy (DCM), ar-
rhythmia, or unknown. IHD was defined as lumen diameter 
stenosis > 50% in at least 1 major coronary artery as deter-
mined by coronary angiography and as diagnosed by old myo-
cardial infarction.
Transthoracic echocardiography:   Echocardiography was per-
formed before tolvaptan treatment upon hospitalization. An 
experienced sonographer obtained all echocardiographic data 
including left ventricular (LV) chamber size, LV ejection frac-
tion (LVEF), severity of mitral regurgitation (MR) and tricus-
pid regurgitation, and dilation of the inferior vena cava (IVC), 
which was interpreted by an experienced staff echocardiogra-
pher. Comprehensive examinations were performed on all of 
the study patients, including M-mode, two-dimensional, con-
ventional Doppler, and color Doppler echocardiography.
Statistics:   Statistical analysis was performed using the Stat 
View statistical software package (Stat View 5; SAS Institute 
INC., Cary, NC). Data are expressed as the mean ± standard 
deviation (SD) or number (%). The significance of differences 
was evaluated using Student’s t-test for continuous variables 
and the χ2 test for categorical variables. Multivariate analysis 
was performed using logistic regression analysis for independ-
Table I.  Patient Characteristics at Baseline in the Non-ARB/ACE-I and 
ARB/ACE-I Groups
Non-ARB/ACE-I group 
(n = 21)
ARB/ACE-I group 
(n = 44)
Age, years 71 ± 14 76 ± 13
Male, n (%)  8 (38) 28 (64)
Weight, kg 57.0 ± 14.8 58.9 ± 12.2
BMI, kg/m2 22.5 ± 4.7 23.7 ± 3.9
Smoking, n (%)  6 (29) 15 (34)
DM, n (%)  4 (20) 17 (39)
HTN, n (%)  9 (43)  38 (86)*
DL, n (%) 14 (67) 24 (55)
HU, n (%) 13 (62) 27 (61)
CKD, n (%) 11 (52) 27 (61)
IHD, n (%)  5 (24)  24 (55)*
SBP, mmHg 102 ± 20 109 ± 18
DBP, mmHg 56 ± 11 59 ± 11
HR, bpm 73 ± 22 76 ± 13
LVEF, % 40 ± 19 44 ± 19
CTR, % 64 ± 9 62 ± 7
Medications
 α-Blocker, n (%) 11 (52) 22 (50)
 β-Blocker, n (%) 13 (62) 28 (64)
 CCB, n (%)  5 (24) 16 (36)
 Loop diuretic, n (%) 18 (86) 38 (86)
 Ald-B, n (%) 10 (48) 24 (55)
 Carperitide, n (%)  7 (33) 16 (36)
 Catecholamine, n (%)  6 (29) 11 (25)
Etiology of HF
 IHD, n (%)  4 (19) 14 (32)
 HTCM, n (%) 1 (5)  5 (11)
 VHD, n (%)  7 (33)  8 (18)
 DCM, n (%)  2 (10)  5 (11)
 Arrhythmia, n (%) 1 (5) 3 (7)
 Unknown, n (%)  6 (29)  9 (20)
BMI indicates body mass index; DM, diabetes mellitus; HTN, hyperten-
sion; DL, dyslipidemia; HU, hyperuricemia; CKD, chronic kidney dis-
ease; IHD, ischemic heart disease; SBP, systolic blood pressure; DBP, di-
astolic BP; HR, heart rate; LVEF, left ventricular ejection fraction; CTR, 
cardiothoracic ratio; CCB, calcium channel blocker; Ald-B, aldosterone 
blocker; HTCM, hypertensive cardiomyopathy; VHD, valvular heart dis-
ease; and DCM, dilated cardiomyopathy. *P < 0.05 versus non-ARB/
ACE-I group.
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ent variables that were associated with the response to the use 
of tolvaptan. A value of P < 0.05 was considered significant.
Results
Patient characteristics at baseline in the non-ARB/ACE-I and 
ARB/ACE-I groups:   Table I shows the patient characteristics 
at baseline in the non-ARB/ACE-I and ARB/ACE-I groups. In 
the non-ARB/ACE-I and ARB/ACE-I groups, the average age 
was 71 and 76 years and the percentage (%) of males was 38% 
and 64%, respectively. There were no significant differences in 
patient characteristics including medications at baseline be-
tween the non-ARB/ACE-I and ARB/ACE-I groups except for 
% HTN and % IHD. % HTN and % IHD in the ARB/ACE-I 
group were significantly higher than those in the non-ARB/
ACE-I group. The average dose of loop diuretic (furosemide) 
before the use of tolvaptan (at baseline) in the non-ARB/ACE-
I and ARB/ACE-I groups was 50 ± 27 and 48 ± 42 mg/day 
(non-ARB/ACE-I versus ARB/ACE-I, P = 0.87), when we 
converted azosemide 30 mg and torasemide 4 mg to furosem-
ide 20 mg. The average number of days of tolvaptan adminis-
tration in the groups was 16 ± 7 and 16 ± 12 days, respectively 
(non-ARB/ACE-I versus ARB/ACE-I, P = 0.83). The initial 
doses (maintenance doses) of tolvaptan were 7.0 ± 2.6 (10.3 ± 
4.0) and 7.0 ± 2.7 (10.0 ± 4.2) mg/day [nonARB/ACE-I versus 
ARB/ACE-I groups, P = 0.60 (P = 0.73)]. Thus, there were no 
significant differences in the duration or doses of tolvaptan 
treatment between the groups. % Carperitide was similar in the 
non-ARB/ACE-I (33%) and ARB/ACE-I (36%) groups, and 
there were no significant differences in the average dose of 
carperitide between the groups [0.02 ± 0.01 μg/kg/minute 
(ARB/ACE-I) versus 0.02 ± 0.01 μg/kg/minute (non-ARB/
ACE-I), P = 0.96]. The % and doses of catecholamines were 
also similar between the groups (data not shown).
Forty-six percent of the patients had reduced EF (LVEF < 
40%), and 12% had de-novo acute decompensated HF. There 
were no significant differences in % etiology of HF between 
the non-ARB/ACE-I and ARB/ACE-I groups. While LVEF at 
baseline was similar in the two groups (Table I), there were no 
significant differences in echocardiographic data such as LV 
chamber size, dilation of IVC, and severity of MR and TR at 
baseline (data not shown).
Biochemical parameters, body weight, cardiothoracic ratio, BP, 
and HR at baseline and after 10 days (at post) in the non-ARB/
ACE-I and ARB/ACE-I groups:   Biochemical parameters at 
baseline and after 10 days in the groups are shown in Table II. 
There were no significant differences in various biochemical 
parameters at baseline between the groups. There were no sig-
nificant changes in various biochemical parameters including 
eGFR between baseline and after 10 days in both groups ex-
cept for serum Na and urine osmolality (Table II and Figure 
1AB). In the ARB/ACE-I group, serum Na at baseline was sig-
nificantly lower than that after 10 days. In addition, in the non-
ARB/ACE-I group, urine osmolality after 10 days was signifi-
cantly less than that at baseline. Body weight and CTR after 10 
days were significantly less than those at baseline in both 
groups (Figure 1CD). There were no significant differences in 
the reductions in body weight and CTR between the groups af-
ter the use of tolvaptan. In addition, there were no significant 
changes in SBP [P = 0.22 (non-ARB/ACE-I group) and P = 
0.68 (ARB/ACE-I group)], DBP (P = 0.052 and P = 0.33) and 
Table II.  Biochemical Parameters at Baseline and Post in the Non-ARB/ACE-I and ARB/ACE-I Groups
Non-ARB/ACE-I group (n = 21) ARB/ACE-I group (n = 44)
Baseline Post Baseline Post
RBC, × 104/mL 366 ± 105 379 ± 103 351 ± 79 363 ± 68
WBC, /mL 5562 ± 2487 6185 ± 5370 6029 ± 2124 6257 ± 1924
Plt, × 104/mL 13.2 ± 6.9 14.7 ± 8.3 18.0 ± 6.7 18.6 ± 6.6
Hemoglobin, g/dL 11.3 ± 2.7 11.7 ± 2.8 10.7 ± 2.0 11.1 ± 1.9
UN, mg/dL 32.8 ± 18.4 31.6 ± 13.7   30 ± 12.7   30 ± 13.2
Cr, mg/dL 1.4 ± 0.5 1.3 ± 0.4 1.5 ± 0.6 1.5 ± 0.9
eGFR, mL/minute/1.73m2 42 ± 21 41 ± 17 40 ± 22 39 ± 20
UA, mg/dL 8.2 ± 3.1 · · · · 6.9 ± 1.8 · · · ·
Na, mEq/L 139 ± 3 140 ± 5 138 ± 5 140 ± 4**
K, mEq/L 4.2 ± 0.5 4.2 ± 0.6 4.3 ± 0.8 4.4 ± 0.6
Cl, mEq/L 102 ± 5 101 ± 6 102 ± 5 104 ± 4
LDL-C, mg/dL 82 ± 23 · · · · 85 ± 34 · · · ·
HDL-C, mg/dL 34 ± 12 · · · · 39 ± 12 · · · ·
TG, mg/dL 99 ± 46 · · · · 84 ± 36 · · · ·
TC, mg/dL 138 ± 31 · · · · 148 ± 33 · · · ·
AST, IU/L 40 ± 21 39 ± 21 28 ± 18 26 ± 12
ALT, IU/L 27 ± 17 34 ± 28 30 ± 44 26 ± 38
LDH, IU/L 263 ± 77 248 ± 64 242 ± 60 223 ± 46
HbA1c, % 6.2 ± 1.0 · · · · 6.2 ± 0.7 · · · ·
BNP, pg/mL 758 ± 482 · · · · 1072 ± 1981 · · · ·
NT-proBNP, pg/mL 6054 ± 4004 · · · · 7280 ± 7277 · · · ·
Urine osmolality, mOsm/L 411 ± 114 256 ± 64* 372 ± 105 291 ± 156
RBC indicates red blood cells; WBC, white blood cells; Plt, platelets; UN, urea nitrogen; Cr, creatinine; eGFR, estimated 
glomerular filtration rate; UA, uric acid; Na, sodium; K, potassium; Cl, chloride; LDL-C, low-density lipoprotein cholester-
ol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; TC, total cholesterol; AST, aspartate transaminase; ALT, 
alanine aminotransferase; LDH, lactate dehydrogenase; HbA1c, hemoglobin A1c; BNP, brain natriuretic peptide; and NT-
proBNP, N-terminal pro-BNP. *P < 0.05, **P < 0.01 versus baseline.
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HR (P = 0.56 and P = 0.32) between at baseline and after 10 
days in both groups. There were no significant changes in time 
courses of SBP and DBP between the non-ARB/ACE-I and 
ARB/ACE-I groups (Figure 2).
Time course of UV for 10 days in the non-ARB/ACE-I and 
ARB/ACE-I groups:   Figure 3 shows the time course of UV. 
UV at baseline in the ARB/ACE-I group was slightly higher 
than that in the non-ARB/ACE-I group (P = 0.09). As shown 
in Figure 3A, UV at baseline (day 0) in the ARB/ACE-I group 
was significantly increased at days 2 and 3, and UV at baseline 
in the non-ARB/ACE-I group was significantly increased at 
days 1, 2, 3, 4, 5, 6, 7, and 9. On the other hand, although UV 
in the non-ARB/ACE-I group was higher than that in the ARB/
ACE-I group from day 1 to day 9, there were no significant 
differences in UV on each day between the groups. Changes in 
UV (UV at each respective day minus UV at baseline) are 
shown in Figure 3B. The non-ARB/ACE-I group showed sig-
nificant differences in the increase in UV at days 1, 4, 5, 6 and 
7 compared with the ARB/ACE-I group. Finally, the average 
change in UV in the non-ARB/ACE-I group was significantly 
higher than that in the ARB/ACE-I group (Figure 3C).
Patient characteristics at baseline in the responders and non-re-
sponders to the use of tolvaptan:   The patients for whom we 
had data regarding UV at baseline and the entire follow-up pe-
riod (n = 44) were divided into 2 groups according to the aver-
age change in UV after the use of tolvaptan: non-responders (n 
= 22, -94 ± 395 mL/day) and responders (n = 22, 939 ± 464 
mL/day). Patient characteristics at baseline in the responders 
and non-responders to the use of tolvaptan are shown in Table 
III. There were no significant differences in patient characteris-
Figure 1.  Changes in estimated glomerular filtration rate (eGFR) (A), serum sodium (Na), body weight (C), and cardiotho-
racic ratio (CTR) (D) between baseline (Day 0) and at 10 days (at post) (values at 10 days minus values at baseline) in the 
non-ARB/ACE-I and ARB/ACE-I groups. **P < 0.01 versus baseline. NS indicates not significant.
Figure 2.  Time courses of systolic blood pressure (SBP) and diastolic BP 
(DBP) in the non-ARB/ACE-I and ARB/ACE-I groups. Black and gray 
lines indicate the ARB/ACE-I and non-ARB/ACE-I groups, respectively.
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tics except for age and % ARB/ACE-I at baseline between the 
responders and non-responders. Age and % ARB/ACE-I in the 
responder group were significantly lower than those in the 
non-responder group. The percent of each medication includ-
ing loop diuretic was similar between the groups. The average 
doses of loop diuretic (furosemide) in the responders and non-
responders were 47 ± 28 and 37 ± 25 mg/day, respectively (re-
sponders versus non-responders, P = 0.29). The starting doses 
(final doses) of tolvaptan in the responders and non-responders 
were 6.8 ± 2.3 (10.3 ± 3.8) and 7.1 ± 3.1 (10.7 ± 3.9) mg/day, 
respectively [responders versus non-responders, P = 0.67 (P = 
0.71)].
With respect to biochemical parameters at baseline, there 
were no significant differences in eGFR [46 ± 25 (responders) 
versus 37 ± 11 mL/minute/1.73m2 (non-responders), P = 0.13], 
BNP (959 ± 654 versus 1272 ± 2714 pg/mL, P = 0.70), NT-
proBNP (8177 ± 7074 versus 7765 ± 8049 pg/mL, P = 0.90), 
or urine osmolality (436 ± 151 versus 351 ± 106 mOsm/L, P = 
0.15) between the responders and non-responders.
Reductions in body weight and CTR and changes in BP and 
HR in the responders and non-responders:   Reductions in 
body weight and CTR (value at baseline minus value after 10 
days) in the responders and non-responders are shown in Fig-
ure 4. There were no differences in body weight [60.2 ± 14.4 
(responders) versus 54.8 ± 9.6 kg (non-responders), P = 0.18] 
and CTR [62.4 ± 6.5 versus 60.3 ± 6.1%, P = 0.28] at baseline 
between the responders and non-responders. The reduction of 
body weight after the use of tolvaptan in the responders was 
significantly higher than that in the non-responders, although 
Figure 3.  Time course of urinary volume (UV) for 10 days (A), changes in UV [UV on each day minus UV at baseline 
(Day 0)] (B), and average changes in UV (C) in the non-ARB/ACE-I and ARB/ACE-I groups. Black bars and lines indicate 
the ARB/ACE-I group, and gray bars and lines indicate the non-ARB/ACE-I group. *P < 0.05, **P < 0.01 versus baseline. #P 
< 0.05, ##P < 0.01 versus ARB/ACE-I group.
Table III.  Patient Characteristics at Baseline in the Non-Responder and 
Responder Groups
Non-responder group 
(n = 22)
Responder group 
(n = 22)
Age, years 80 ± 8 71 ± 14*
Male, n (%) 14 (64) 12 (55)
Weight, kg 55.6 ± 9.5 60.2 ± 14.4
BMI, kg/m2 22.7 ± 3.9 22.9 ± 4.3
Smoking, n (%)  7 (32)  9 (41)
DM, n (%)  6 (27)  7 (32)
HTN, n (%) 18 (82) 15 (68)
DL, n (%) 13 (59)  9 (41)
HU, n (%) 10 (45) 11 (50)
CKD, n (%) 13 (59) 11 (50)
IHD, n (%) 13 (59) 11 (50)
SBP, mmHg 109 ± 20 106 ± 19
DBP, mmHg 58 ± 10 58 ± 13
HR, bpm 70 ± 16 81 ± 18
LVEF, % 46 ± 18 42 ± 21
Cardiothoracic ratio, % 60 ± 6 62 ± 7
Medications
 ARB/ACE-I, n (%) 19 (86) 11 (50)*
 β-Blocker, n (%) 15 (68) 12 (55)
 CCB, n (%)  6 (27)  8 (36)
 Loop diuretic, n (%) 18 (82) 18 (82)
ARB/ACE-I indicates angiotensin II type 1 receptor blocker/angiotensin 
converting enzyme inhibitor. Other abbreviations as shown in Table I. *P < 
0.05 versus non-responder group.
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there was no difference in the reduction of CTR between the 
groups. In addition, there were no significant changes in SBP 
[P = 0.61 (non-responders) and P = 0.54 (responders)], DBP (P 
= 0.65 and P = 0.37), and HR (P = 0.95 and P = 0.22) between 
at baseline and after 10 days in both groups.
Associations between the response to the use of tolvaptan and 
various factors:   Finally, we analyzed the associations between 
the response to the use of tolvaptan and various factors. In a lo-
gistic regression analysis (Table IV), a response to the use of 
tolvaptan was independently associated with the non-use of 
ARB/ACE-I, but not with age, gender, body mass index, loop 
diuretic, or human atrial natriuretic peptide.
Discussion
The present study had two major findings: 1) the increase 
in UV after the use of tolvaptan in the non-ARB/ACE-I group 
was significantly higher than that in the ARB/ACE-I group, 
and 2) a response to the use of tolvaptan was independently as-
sociated with the non-use of ARB/ACE-I.
The most interesting observation in this study was that 
the response to the use of tolvaptan was independently associ-
ated with the non-use of ARB/ACE-I. Thus, tolvaptan alone 
had a sufficient diuretic effect when patients did not receive 
ARB/ACE-I before starting tolvaptan. Although ARB/ACE-I 
is the first-choice strategy for the treatment of HF,1,2,15) 
tolvaptan induced a significant increase in UV in HF patients 
without ARB/ACE-I. Almost all of the patients received a loop 
diuretic, and the combination of loop diuretic and ARB/ACE-I 
is known to have a synergistic effect. ARB/ACE-I enhances 
the diuretic effect of a loop diuretic. Thus, ARB/ACE-I can 
overcome the deleterious effects of a loop diuretic. In fact, UV 
at baseline in the ARB/ACE-I group was slightly higher than 
that in the non-ARB/ACE-I group in this study. Under these 
conditions, tolvaptan may not induce an additional diuretic ef-
fect in the ARB/ACE-I group, although the mechanism of the 
diuretic effect of a loop diuretic is different from that of 
tolvaptan, which is a vasopressin type 2 receptor antagonist.7-9) 
In addition, tolvaptan did not exert its effect by activating the 
renin-angiotensin system,19) whereas furosemide increased 
plasma arginine vasopressin concentrations in addition to plas-
ma renin activity.20) The combination of a loop diuretic and 
tolvaptan may also have a synergistic diuretic effect. Therefore, 
the increase in UV after the use of tolvaptan in the non-ARB/
ACE-I group was significantly higher than that in the ARB/
ACE-I group. Although the non-ARB/ACE-I group did not 
benefit from the use of ARB/ACE-I for the treatment of HF, 
this disadvantage is considered to have been supplemented by 
the use of tolvaptan.
There were no differences in eGFR at baseline between 
the ARB/ACE-I and non-ARB/ACE-I groups or between the 
responders and non-responders. Renal function may affect the 
response of UV to tolvaptan. Patients with severe renal failure 
who received tolvaptan showed increased UV and decreased 
osmolality.21) In contrast, patients with low eGFRs tended to 
show poor responses to short-term tolvaptan treatment.22) In 
this study, renal function was not associated with the response 
to tolvaptan.
There were no adverse effects on biochemical parameters 
in this study. Tolvaptan is useful for increasing UV without 
impairing renal function.23) There were no significant changes 
in eGFR or serum Cr between before and after tolvaptan thera-
py. Hyponatremia is a common electrolyte disorder in patients 
with decompensated HF.24) In worsening HF, hyponatremia is 
one of several predictors of mortality.25) High-dose loop diuret-
ics have several adverse effects including renal impairment and 
hyponatremia,6) and the average dose of the loop diuretic furo-
semide in this study was only 40-50 mg/day. Tolvaptan im-
proved serum Na levels in patients with hyponatremia,26) al-
though the average dose of tolvaptan was only about 10 mg/
day. Even though patients received a combination of loop diu-
retic and tolvaptan, the doses of both medications were low 
and did not have any adverse effects on biochemical parame-
ters in this study.
There were differences in patient characteristics at base-
line including %HTN and %IHD between the non-ARB/ACE-
I and ARB/ACE-I groups (Table I). The ARB/ACE-I group 
showed higher %HTN and %IHD than the non-ARB/ACE-I 
group. Generally, patients with HTN are more likely to receive 
ARB/ACE-I to lower BP compared to patients without HTN, 
and IHD patients are more likely to receive ARB/ACE-I to 
prevent cardiac remodeling compared to non-IHD patients. In 
addition, while SBP/DBP levels in both groups were low 
(about 100-110/60 mmHg), there was no difference between 
the groups. The non-ARB/ACE-I group did not need to receive 
ARB/ACE-I because of a lower BP. When a multivariate anal-
Figure 4.  Reductions in body weight and cardiothoracic ratio (CTR) in 
the responders and non-responders. Closed and open bars indicate the 
non-responders and responders. NS indicates not significant. *P < 0.05 
versus non-responders.
Table IV.  Association Between the Responders of the Use of Tolvaptan 
and Various Factors
Factor OR (95% CI) P
Age 1.081 (0.999-1.169) 0.053
Gender (Male) 0.462 (0.100-2.145) 0.324
BMI 0.972 (0.798-1.185) 0.78
Loop diuretics 0.535 (0.059-4.874) 0.579
Carperitide 0.145 (0.010-2.045) 0.153
ARB/ACE-I 0.080 (0.008-0.858) 0.037
OR indicates odds ratio; and CI, confidence interval. Other abbreviations 
as shown in Tables I and II.
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ysis was performed (Table IV), independent variables that 
were associated with the response to tolvaptan were selected. 
HTN and IHD were not included as independent variables be-
cause there were no differences in %HTN and %IHD between 
the non-responder and responder groups (Table III). Finally, 
we found that a response to the use of tolvaptan was independ-
ently associated with the non-use of ARB/ACE-I.
Imamura, et al reported that a decrease in urine osmolali-
ty of more than 26% from a baseline >352 mOsm/L for the 
first 4-6 hours predicts responders to tolvaptan.22) In this study, 
there was no significant difference in urine osmolality at base-
line between responders and non-responders to the use of 
ARB/ACE-I. There are at least two possible explanations for 
this discrepancy. First, urine osmolality at baseline in the non-
ARB/ACE-I and ARB/ACE-I groups was 411 ± 114 and 372 
± 105, respectively, and both of these values were relatively 
high. Second, in their study, a responder/non-responder to 
tolvaptan was determined as having an increase/decrease in 
UV during the 24 hours after tolvaptan treatment.22) On the 
other hand, we measured UV during the 10 days after 
tolvaptan treatment.
In this study, % β-blocker use was only 62-64%. There 
are two possible explanations for this relatively low value. 
First, 46% of the overall patients had LVEF of less than 40%. 
Second, 12% of the patients showed de-novo acute decompen-
sated HF. There are several limitations to the present study. 
First, it was retrospective and from a single center with a rela-
tively small sample size. There is no prognostic information 
associated with tolvaptan. Second, we did not confirm im-
provements in cardiac function by ultrasound cardiography, al-
though we analyzed body weight and CTR. Third, patients re-
ceived different doses and kinds of medications, although we 
assessed the % use of each medication between the responders 
and non-responders. Therefore, a large controlled randomized 
study should be performed to confirm the characteristics of pa-
tients who respond to the use of tolvaptan.
In conclusion, tolvaptan alone might induce an increase 
in UV in acute decompensated HF patients without the admin-
istration of ARB/ACE-I, although ARB/ACE-I is the first-
choice strategy for the treatment of HF. If sufficient UV can be 
achieved under the administration of ARB/ACE-I, this would 
be advantageous for the treatment of HF. Tolvaptan alone with-
out ARB/ACE-I induced a sufficient increase in UV in decom-
pensated HF patients, and may also provide a complementary 
benefit for the treatment of HF.
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